Capstone Therapeutics Corp
OTC:CAPS

Watchlist Manager
Capstone Therapeutics Corp Logo
Capstone Therapeutics Corp
OTC:CAPS
Watchlist
Price: 0.76 USD 1.33%
Market Cap: 6.3m USD

Relative Value

CAPS latest financial reports are more than 3 years old.
CAPS doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CAPS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAPS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-18
Median 5Y
-60.1
Industry
24.1
vs History
vs Industry
Median 3Y
-22.3
Median 5Y
-74.2
Industry
21.8
vs History
vs Industry
Median 3Y
-28.1
Median 5Y
-93.8
Industry
23.8
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-37.8
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-55.9
Median 5Y
-176.6
Industry
6.3
vs History
vs Industry
Median 3Y
-53
Median 5Y
-167.5
Industry
6.7
vs History
vs Industry
Median 3Y
-24.1
Median 5Y
-76
Industry
7.9
vs History
vs Industry
Median 3Y
-24.1
Median 5Y
-76
Industry
6.3
vs History
vs Industry
Median 3Y
-43.7
Median 5Y
-138.2
Industry
5.5

Multiples Across Competitors

CAPS Competitors Multiples
Capstone Therapeutics Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Capstone Therapeutics Corp
OTC:CAPS
6.3m USD 0 -3 -12.9 -12.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 623 419.7 -159 807.1 -194 056.8 -191 842.4
US
Abbvie Inc
NYSE:ABBV
407.6B USD 6.8 173 16.8 23.8
US
Amgen Inc
NASDAQ:AMGN
179.2B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.4B USD 5.4 19.2 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.5B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.2 -534.6 -582.2 -566.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83B USD 5.8 18 17.3 19.6
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.6B USD 16.4 1 207.3 162.8 197.4
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.3 59.9
P/S Multiple
Revenue Growth P/S to Growth
US
Capstone Therapeutics Corp
OTC:CAPS
Average P/S: 3 362 558.2
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 623 419.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 095.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Capstone Therapeutics Corp
OTC:CAPS
Average P/E: 191
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 807.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 207.3
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Capstone Therapeutics Corp
OTC:CAPS
Average EV/EBITDA: 40.3
Negative Multiple: -12.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 056.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.8
N/A N/A
NL
argenx SE
XBRU:ARGX
58.3
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Capstone Therapeutics Corp
OTC:CAPS
Average EV/EBIT: 46.5
Negative Multiple: -12.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 842.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.4
N/A N/A
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A